SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma trades jubilantly on reporting 76% surge in Q3 net profit

23 Jan 2013 Evaluate

Ajanta Pharma is currently trading at Rs. 440.00, up by 31.10 points or 7.61% from its previous closing of Rs. 408.90 on the BSE.

The scrip opened at Rs. 411.90 and has touched a high and low of Rs. 443.80 and Rs. 404.15 respectively. So far 167302 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 505.00 on 21-Sep-2012 and a 52 week low of Rs. 161.98 on 24-Jan-2012.

Last one week high and low of the scrip stood at Rs. 443.80 and Rs. 390.00 respectively. The current market cap of the company is Rs. 1014.31 crore.

The promoters holding in the company stood at 72.70% while Institutions and Non-Institutions held 1.37% and 25.93% respectively.

Ajanta Pharma has reported results for third quarter ended December 31, 2012.

The company has registered a rise of 75.96% in its net profit at Rs 32.57 crore in Q3FY13 as compared to Rs 18.51 crore in the corresponding quarter previous year. The total income from operation of the company has increased by 39.65% to Rs 229.34 crore for the quarter under review as compared to Rs 164.23 crore in the same quarter last year.

Ajanta Pharma (APL) is engaged manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.

Ajanta Pharma Share Price

3098.00 33.05 (1.08%)
12-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.90
Dr. Reddys Lab 1270.10
Cipla 1295.15
Zydus Lifesciences 932.00
Lupin 2240.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×